This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maier, K. Articles by Diem, R. Search for Related Content PubMed PubMed Citation Articles by Maier, K. Articles by Diem, R.

(American Journal of Pathology. 2006;169:1353-1364.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.060159

Effects of Glatiramer Acetate and Interferon-ß on Neurodegeneration in a Model of Multiple Sclerosis

A Comparative Study

Katharina Maier^*, Antje V. Kuhnert^*, Naimeh Taheri^*, Muriel B. Sättler^*, Maria K. Storch, Sarah K. Williams^*, Mathias Bähr^* and Ricarda Diem^*

From the Neurologische Universitätsklinik,^* Göttingen, Germany; and the Neurologische Universitätsklinik, Graz, Austria

Axonal destruction and neuronal loss occur early during multiple sclerosis (MS), an autoimmune in-flammatory central nervous system disease that frequently manifests with acute optic neuritis. Glatiramer acetate (GA) and interferon-ß-1b (IFN-ß-1b) are two immunomodulatory agents that have been shown to decrease the frequency of MS relapses. However, the question of whether these substances can slow neurodegeneration in MS patients is the subject of controversy. In a rat model of experimental autoimmune encephalomyelitis, we investigated the effects of GA and IFN-ß-1b on the survival of retinal ganglion cells (RGCs), the neurons that form the axons of the optic nerve. For each substance, therapy was started 14 days before immunization, on the day of immunization, or on the day of clinical disease onset. After myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis became clinically manifest, optic neuritis was monitored by recording visual evoked potentials. The function of RGCs was measured by electroretinograms. Although early GA or IFN-ß-1b treatment showed benefit on disease activity, only treatment with GA exerted protective effects on RGCs, as revealed by measuring neurodegeneration and neuronal function. Furthermore, we demonstrate that this GA-induced neuroprotection does not exclusively depend on the reduction of inflammatory infiltrates within the optic nerve.

This article has been cited by other articles:

				S. R. Brenner, M.G. Brown, S. Kirby, C. Skedgel, J.D. Fisk, T.J. Murray, V. Bhan, and I.S. Sketris HOW EFFECTIVE ARE DISEASE-MODIFYING DRUGS IN DELAYING PROGRESSION IN RELAPSING-ONSET MS? Neurology, August 19, 2008; 71(8): 615 - 616. [Full Text] [PDF]

				R. Aharoni, A. Herschkovitz, R. Eilam, M. Blumberg-Hazan, M. Sela, W. Bruck, and R. Arnon Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis PNAS, August 12, 2008; 105(32): 11358 - 11363. [Abstract] [Full Text] [PDF]

				X. Qi, L. Sun, A. S. Lewin, W. W. Hauswirth, and J. Guy Long-term Suppression of Neurodegeneration in Chronic Experimental Optic Neuritis: Antioxidant Gene Therapy Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5360 - 5370. [Abstract] [Full Text] [PDF]

				K. S. Shindler, E. Ventura, T. S. Rex, P. Elliott, and A. Rostami SIRT1 Activation Confers Neuroprotection in Experimental Optic Neuritis Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3602 - 3609. [Abstract] [Full Text] [PDF]

				F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]